The European Commission is now expecting to make a final decision on the updated version of the two drugmakers’ original Comirnaty shot within the next couple of weeks.
The EMA said the decision by the CHMP will “further extend the arsenal of available vaccines to protect people against COVID-19 as the pandemic continues and new waves of infections are anticipated in the cold season.”
The new 30 µg booster shot is bivalent – with mRNA coding for spike protein from both the original wild-type SARS-CoV-2 virus as well as the BA.4/BA.5 subvariant – should be approved for use in people aged 12 years and above who have received at least a primary course of vaccination against COVID-19, according to the EMA’s update.
